Recipharm Appoints Prof. Hans Lennernäs to One of its Operating Boards
News Feb 05, 2013
Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company's Board of Directors.
Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of 24.5 MEuro.
His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.
Dr. Lennernäs has served as the Principal Investigator in an extensive collaboration with the Food Drug & Administration, USA, University of Michigan, USA, and Medical Product Agency, Sweden over the course of several years in which he developed a new guideline for the Biopharmaceutics Classification System.
He has established an extensive and widely used human permeability database.
In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.
“I am very much looking forward to serving on the Board of Directors at Recipharm Pharmaceutical Development AB. Indeed, this is a company with an excellent track record and an impressive long term strategy in place”, Hans Lennernäs commented.
“We are very pleased to welcome a Board Member of Hans Lennernäs calibre”, remarked General Manager Maria Lundberg. “His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the Board. I look forward to Recipharm benefiting from his Board level contribution and insights that will help the company perpetuate its track record of commercial success”.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE